美國Nabi Biopharmaceuticals
美國Nabi生物制藥公司研發的一種用于治療尼古丁成癮和預防復吸疫苗NieVax(尼古丁接合疫苗)獲得FDA授予的快通道審批地位。該疫苗將在第二季度進入Ⅱ期概念驗證臨床試驗階段,包括300位患者,試驗結果將于2007年下半年得出。在未來幾年里,戒煙市場將發生明顯變化。
PentaStaph (五金黃色葡萄球菌疫苗)
Nabi Biopharmaceuticals is focused on developing a series of first and second generation products that address unmet medical needs and offer opportunities in our core business areas: nicotine addiction and gram-positive bacterial infections.
Driven by our clinical development programs, we are focused on building value and are seeking partners for our vaccine programs: NicVAX? (Nicotine Conjugate Vaccine) and PentaStaph? (Staphylococcal Polysaccharide Conjugate and Toxoid Vaccine). Our headquarters is located in Rockville, Maryland along with our Research and Development facility.